Running Title: Hemolysis-associated pulmonary hypertension. 
Introduction
Intravascular hemolysis presents with pleiotropic clinical manifestations including anemia, abdominal pain, dysphagia, erectile dysfunction, pulmonary arterial hypertension (PAH), renal failure, and platelet activation and thrombosis, all of which are considered direct sequelae of erythrocyte lysis 1, 2 . Another known consequence of intravascular hemolysis is unexpected sudden death [2] [3] [4] [5] , which accounts for 12-26% of all deaths in patients with sickle cell disease (SCD) [6] [7] [8] [9] [10] , and is frequently associated with other hemolytic diseases such as thalassemia, hemolytic uremic syndrome (HUS), paroxysmal nocturnal hemoglobinuria (PNH), ABO mismatch transfusion reaction, and autoimmune hemolytic anemia 11 . Although the mechanism(s) of hemolysis-associated sudden death is poorly defined, PAH with characteristic histopathological findings including plexiform, concentric medial hyperplastic pulmonary vascular lesions, and in situ pulmonary arterial thrombosis 5,12-14 is suspected to be a strong, albeit still unproven, cause of death in acute hemolytic disorders 5, [12] [13] [14] [15] .
Nitric oxide (NO) insufficiency is suspected to play an important role in the pathogenesis of hemolysis-mediated PAH 1 . Nitric oxide (NO) produced by the endothelium plays a fundamental role in regulating basal vasomotor tone, blood pressure, and organ blood flow distribution; it also inhibits platelet activation and expression of molecules that promote adhesion of platelets and leukocytes to the endothelium 1, 16, 17 . Nitric oxide-induced vasodilation derives from its stimulatory effect on soluble guanylyl cyclase with subsequent formation of cyclic GMP (cGMP) causing vascular smooth muscle relaxation. NO bioavailability can be dramatically reduced by the release of cell free hemoglobin. The rate of NO reacting with hemoglobin
For personal use only. on May 3, 2017. by guest www.bloodjournal.org From encapsulated within erythrocytes is reduced by nearly three orders of magnitude by major diffusion barriers imposed by a cell-free zone along the endothelium in laminar flowing blood and the unstirred layer, an area of non-flowing blood around the external surface of the erythrocytes 18 . The release of hemoglobin into plasma during intravascular hemolysis removes these diffusion barriers, increasing the scavenging of NO. The reduced NO bioavailability leads to a clinical state of endothelial dysfunction, smooth muscle constriction, and increased peripheral resistance, which in the pulmonary circulation are likely involved in the development of hemolysis-associated PAH 12 . Platelet activation and thrombus formation is another consequence of intravascular hemolysis. Increased platelet activation, well established in patients with hemolytic anemias such as SCD, β -thalassemia, and PNH 19, 20 , is another pathogenic factor that contributes to the clinical manifestations of these disorders including PAH 20, 21 . For example, new and old thrombi in the pulmonary vasculature were found by autopsy in up to 75% of SCD 4, 22 . Despite strong clinical evidence, investigations on either the role of platelet activation in hemolysis-associated PAH or effective therapies have been hampered by practical and ethical challenges and the lack of adequate animal models. As a consequence, current treatment for PAH associated with hemolytic disorders is based on limited evidence or expert opinion 15 . These considerations highlight the need for reliable and reproducible animal models of hemolysis-associated fatal PAH. To date, several animal models, such as the free water-induced intravascular hemolysis dog model, and the SCD and incompatible blood transfusion mouse models, have provided many insights into the pathogenesis of hemolysis and hemolysisassociated PAH [23] [24] [25] . However, they have not been utilized to investigate the direct For personal use only. on May 3, 2017. by guest www.bloodjournal.org From contribution of hemolysis-associated fatal PAH to the pathogenesis of sudden death in hemolytic disorders. Moreover, the precise underlying mechanisms of NO insufficiency and platelet activation in hemolysis-associated PAH and/or sudden death still require further investigation.
Recently, we generated an intravascular hemolysis model in which varying degrees of hemolysis can be conditionally induced by the administration of intermedilysin (ILY) to transgenic mice expressing human CD59 (hCD59) only in their erythrocytes (ThCD59 RBC )
26
. ILY, a bacterial pore-forming toxin, is potently hemolytic to human and to mouse erythrocytes transgenically expressing hCD59, but not at all hemolytic in other animal species including wild type (WT) mice 26, 28 , through specific interaction of ILY with hCD59 26, 27 . Using this model, we document here that reduced NO bioavailability and platelet activation/aggregation play a critical role in the pathogenesis of hemolysis-associated fatal PAH.
Materials and Methods
Animal studies were approved by Harvard Medical School Institutional Animal Care and Use Committee.
Preparation of recombinant ILY:
We purified His-tagged recombinant ILY as described previously
27
.
Hypotonics, PLY, and melittin-mediated hemolysis on ThCD59 RBC 's erythrocytes:
Pneumolysin (PLY) and melittin were purchased from Dr. James C. Paton's laboratory 
Administration of ILY and evaluation of mouse death:
The volume of ILY injected was 5 µl/g body weight, and the concentration of ILY in the injection buffer (PBS) was adjusted according to experimental objectives so that the volume remained constant.
The tail vein injection was used to administer ILY with constant velocity, which also applied to jugular vein injection except this treatment was used for the RVSP measurement and echocardiographic analysis as described below. The constant velocities of rapid and slow tail vein injection were 10 μl/second and 1.67 μl/second, respectively. We observed the number of surviving or dead mice or the survival time in the mice that died within 15 min after ILY injection.
The pretreatment with sildenafil and antithrombotic agents: Before the administration of ILY, we pretreated mice orally with sildenafil (100 µg/g/day, Pfizer) through gavage for 10 days, clopidogrel (30 µg/g, Sigma) orally through gavage at 1 Partners, Inc.), or hirudin (1 mg/kg, Cabiochem) by i.v. injection at 5 min.
Right heart pressure measurements: Mice were anesthetized with a ketamine (90 mg/kg) and xyaline (10 mg/kg). An incision was made on the ventral side of the neck to 
Results

Further characterization of the ILY-mediated hemolysis model
We have previously reported the generation of an ILY-mediated rapid, specific, and conditional erythrocyte ablation model using ThCD59 RBC mice that specifically express hCD59 on erythrocytes under the control of the α-hemoglobin promoter
26
. Since hCD59 protein expressed in mouse erythrocytes under the control of the hemoglobin promoter can "jump" to the endothelium probably through its GPI 
Intravenous injection of ILY in
Cause of sudden death in acute hemolysis
To assess the potential role of PAH as a determinant of mortality after acute hemolysis, as suspected for many hemolytic disorders (Figure 3 , B and C and Videos S1-4). Importantly, the time interval needed to achieve maximal right ventricle dilation (end-diastolic volume) was significantly shorter in mice treated with the lethal ILY 140 FI dose than in those treated with ILY 140 SI ( Figure 3D and Videos S1-4). Furthermore, values of MABP and right heart function in mice treated with either ILY 140 SI or ILY 70 FI returned to normal levels after a transient decrease ( Figure 3A and Videos S1-4). No changes in hemodynamic or echo diagnostic parameters were observed in WT mice after . We have previously reported that ILY injection in
ThCD59
RBC mice markedly decreased NO levels and increased platelet activation, as
shown by an increase in serum soluble P-selectin (sP-selectin) levels
26
. Here, we confirmed that the NO levels were significantly reduced in the ThCD59 RBC mice injected Figure 4D ) that was not observed in WT mice.
At the histological level, we also observed more extensive P-selectin staining, indicative of platelet activation/aggregation 34 , and integrin αIIb, a specific marker of platelet activation 30, 35 , in the small perialveolar pulmonary vessels in the ThCD59 
Sildenafil rescues hemolysis-associated fatal PAH
To investigate the role of NO in the pathogenesis of hemolysis-associated PAH,
we pretreated ThCD59 RBC mice with sildenafil for ten days (100 mg/kg, oral daily dose).
Sildenafil is a specific phosphodiesterase-5 (PDE-5) inhibitor that increases cGMP levels and thereby potentiates NO-dependent signaling 23 . Sildenafil pretreatment resulted in a significant increase in the levels of cGMP in the lung of ThCD59 RBC mice compared with no pretreatment ( Figure 6A ) and greatly reduced their mortality rate 
Compared to ThCD59
RBC mice without any treatment, those pre-treated with neuraminidase, clopidogrel, integrilin, or sildenafil had lower sP-selectin levels, less lung integrin-αIIb and P-selectin staining, and higher platelet counts (with the exception of neuraminidase-pretreated mice, which had the lowest platelet counts due to depletion) ( Figure 7 , B-E). In summary, these results also demonstrate that platelet activation correlates with the severity of hemolysis-associated PAH. Because bleeding precluded right-ventricle catheterization to measure directly RRRVSP, in mice pre-treated with neuraminidase or clopidogrel, we assessed the hemodynamic consequence of hemolysis-associated PAH indirectly by echocardiographic monitoring of right heart function. ThCD59 RBC mice pretreated with either a platelet depleting or a platelet 
Discussion
The decreased NO bioavailability has long been suspected to participate in the pathogenesis of hemolysis-mediated PAH 1 . This notion is now further supported by our experimental results showing that NO levels were dramatically reduced after ILYinduced hemolysis. Of note, we did not find that the magnitude of NO-insufficiency correlated with the severity of the PAH. This lack of correlation may result from the short-half of NO that precludes our assessing dynamic changes in NO levels in our model system soon after ILY-mediated hemolysis. Nevertheless, the fact that . Thus, how endothelial dysfunction contributes to the pathogenesis of hemolysis-associated complications will require further investigation.
For personal use only. on May 3, 2017. by guest www.bloodjournal.org From A critical role of platelet activation in hemolysis-induced fatal PAH and death is also supported by the concordant results after pharamacological interventions with agents such as sildenafil, which increase activity of the NO-signaling pathway, neuraminidase, which depletes the circulating platelet pool, and clopidogrel or integrilin, platelet inhibitors. All these agents reduced the rate of RVSP (RRRVSP) increase and attenuated the deterioration of right ventricle function. Consistent with this conclusion is the observation that the RRRVSP after ILY injection correlates positively with the death rate and level of platelet activation, and negatively with the survival time after injection.
These results highlight inhibition of platelet activation as a critical avenue for the pharmacological treatment of hemolysis-associated PAH and death. Of note, an NIHfunded study of sildenafil for the treatment of pulmonary hypertension in sickle cell disease was recently stopped due to increased incidence of pain crises (http://www.rhoworld.com/rho/federal-research/projects/walk-phasst). However, whether treating patients with other hemolytic disorders with sildenafil or other agents that increase nitric oxide has potential risks is unclear. Another interesting finding in our studies is that thrombosis is specific to pulmonary vasculature. The underlying mechanism for this phenomenon is unclear. We reason that reduced NO bioavailability due to the scavenging effect of cell-free hemoglobin in acute hemolysis results in the following two consequences: will specifically increase pulmonary vascular tone, and it will also lower the threshold for platelet activation, which leads to platelet thrombosis and, in turn, a further increase in pulmonary vascular resistance and pulmonary artery pressure. The animals died not simply from platelet-dependent thrombosis, but from acute right heart failure brought about by the acute increase in pulmonary vascular resistance secondary to both the increase in pulmonary vascular tone and platelet-dependent thrombosis. In an acute experiment, it is very difficult to dissociate these two events from one another in vivo;
however, the pharmacological data using platelet inhibitors support the view that platelet-dependent thrombosis is a major contributor to the pathophysiology. The quantitative contribution of these two mechanisms--an increase in pulmonary vascular tone and an increase in platelet activation/thrombosis--to the development of hemolysisassociated fatal PAH in both acute and chronic experimental settings is beyond the scope of this study.
In summary, we demonstrate that dramatically reduced NO bioavailability associated with massive hemolysis results in extensive platelet activation, coagulation pathway activation, and thrombosis, thereby leading to PAH, right ventricle failure, and death. These results indicate that the dramatic increase in platelet activation due to rapidly reduced NO in acute intravascular hemolysis plays a critical role in the hemolysis-associated (fatal) PAH. Importantly, these results strongly support the notion that the inhibition of platelet activation and enhancement NO bioavailability (with sildenafil) in acute hemolysis may be critical approaches for the treatment and prevention of hemolysis-associated PAH.
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